ClinicalTrials.gg

Program

DA-2811

A development code. Also written as “DA-2811-C” and “DA-2811-R”.

Its studies are mostly in Diabetes Mellitus, led by Dong-A ST.

Furthest: phase 4, since Feb 15, 20234 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dong-A ST41 open or runningphase 4since Feb 15, 2023Jul 13, 2020Dec 2026phase 2 · NCT07239440

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 13, 2020First study: phase 1 study in HealthyFirst studyNCT04473417 · 60 enrolled · Korea, Republic of
  2. Jun 16, 2021Phase 1 study in HealthyNCT04938752 · 30 enrolled · Korea, Republic of
  3. Feb 15, 2023Phase 4 study in Diabetes MellitusNCT05743907 · 231 enrolled · Korea, Republic of
  4. Nov 16, 2025Phase 2 study in Diabetes MellitusNCT07239440 · 288 planned · South Korea

Ahead

  1. Dec 2026Primary completion: phase 2 study in Diabetes MellitusNCT07239440

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07239440Diabetes Mellitus · South Korea2Not yet recruitingDec 2026288
NCT05743907Diabetes Mellitus · Korea, Republic of4CompletedMar 10, 2025231
NCT04938752Healthy · Korea, Republic of1CompletedAug 20, 202130
NCT04473417Healthy · Korea, Republic of1CompletedAug 26, 202060

How it is read

Names in the registry

  • “DA-2811”, 6 entries
  • “DA-2811-C”, 1 entry
  • “DA-2811-R”, 1 entry

Codes read as this program: DA2811.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.